Sullivan KM, et al. - This study involved a comparison between scleroderma patients who underwent myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation or immunosuppression by means of 12 monthly infusions of cyclophosphamide. The findings revealed the long-term benefits of myeloablative autologous hematopoietic stem-cell transplantation in these patients, including improved event-free and overall survival, at a cost of increased expected toxicity. Compared with previous reports of nonmyeloablative transplantation, lower rates of treatment-related death and post-transplantation use of disease-modifying antirheumatic drugs were reported in this study.